CanSino Biologics, which developed a Covid-19 vaccine candidate with the Chinese military’s research arm, will start testing its vaccine candidate on humans in Russia as part of its global search for the coronavirus cure.The drug maker has initiated phase three of human trials for its Ad5-nCoV vaccine candidate after receiving the green light from the health ministry in Moscow, it said in a statement on Wednesday. It will partner NPO Petrovax Pharm for the clinical trials.The move sparked a…